Market Research Logo

Hemophilia Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Hemophilia Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins. Hemophilia treatment mainly depends on its severity. The treatment includes timely replacement of the specific clotting factor. Increasing number of hemophilic patient requiring treatment and increased diagnosis rate for Hemophilia are major factors anticipated to drive market growth.
Market Dynamics
The major factors driving growth of the Hemophilia treatment market is increasing diagnosis rate. In the U.S., majority of Hemophilia cases are diagnosed at a very young age. According to CDC, the median age for diagnosis is one month for individuals with severe symptoms, 8 months for individuals with moderate Hemophilia, and 36 months for people with mild Hemophilia. Hemophilia treatment is more costly and less effective in 25% of individuals with severe type A disease and in the three percent of individuals with severe type B disease who produce neutralizing inhibitors against factor VIII and factor IX, respectively. Various ongoing treatments such as gene therapy can significantly improve the quality of life for Hemophilia patients by eradicating frequent hospital visits and infusions and shifting patients from severe to mild Hemophilia. Increasing R&D investments and product innovations by many industry players is expected to drive growth of the market over the forecast period. For instance, in 2016, FDA approved Bayer’s Kovaltry drug, a low-frequency dosage for Hemophilia A, which requires two to three doses per week.
Key features of the study:

This report provides in-depth analysis of Hemophilia treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global Hemophilia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global Hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Hemophilia treatment market

Detailed Segmentation:

Global Hemophilia Treatment Market, By Product Type:

Recombinant coagulation factor
Plasma derived coagulation factor
Antifibrinolytic agents
Desmopressin

Global Hemophilia Treatment Market, By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

Global Hemophilia Treatment Market, By Geography:

North America

By Product Type:

Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin

By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

By Country:

U.S.
Canada

Latin America

By Product Type:

Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin

By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Product Type:

Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin

By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Product Type:

Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin

By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Product Type:

Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin

By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

By Country:

GCC
Israel
Rest of Middle East

Africa

By Product Type:

Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin

By Disease Type:

Hemophilia A
Hemophilia B
Hemophilia C

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Baxalta *

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies

Baxter International, Inc.
Biogen Idec, Inc.
Bayer AG
CSL Behring
Chugai Pharmaceutical Co.
Ferring B.V.
Genentech, Inc.
Hospira, Inc.
Kedrion
Novo Nordisk
Octapharma AG
Pfizer, Inc.
Sanofi SA
Shire Plc.
Swedish Orphan Biovitrum AB

“*” marked represents similar segmentation in other categories in the respective section.


Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Disease Type
Market Snippet, By Region
Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Key Highlights
New Therapy Developments
Regulatory Scenario
Regulatory Guidelines
Global Hemophilia Treatment Market, By Product Type, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Recombinant coagulation factor concentrates
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Plasma derived coagulation factor concentrates
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Antifibrinolytic agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Desmopressin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Hemophilia Treatment Market, By Disease Type, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hemophilia A
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Hemophilia B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Hemophilia C
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Hemophilia Treatment Market, By Region, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017 – 2026
North America
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.S.
Canada
Latin America
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
China
India
Japan
Australia
South Korea
ASEAN
Rest of APAC
Middle East
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
South Africa
Central Africa
North Africa
Competitive Landscape
Heat Map Analysis
Company Profiles
Baxalta*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Baxter International, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Biogen Idec, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Bayer AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
CSL Behring
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Chugai Pharmaceutical Co.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Ferring B.V.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Genentech, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Hospira, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Kedrion
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Novo Nordisk
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Octapharma AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Pfizer, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Sanofi SA
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Shire Plc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Swedish Orphan Biovitrum AB
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Analyst Views
Section
References
Research Methodology
About us and Sales Contact
*Browse 22 market data tables and 25 figures on \Global Hemophilia Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report